Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
BLENREP is indicated in adults for the treatment of multiple myeloma:1
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
- In combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide
After first relapse, patients may be prescribed a BLENREP combination and they may have questions regarding their treatment. Below is some guidance on how you can support patients prescribed BLENREP, including what to make patients aware of, practical eye care advice, questions to ask them to assess if they are experiencing any side effects, collaborating with an eye care professional to manage eye-related side effects, and defining roles and responsibilities of the patient’s care team during treatment.
Please refer to the SPC before initiating treatment for full guidance.
Getting started with BLENREP
BLENREP combinations are a treatment option for your eligible multiple myeloma patients after their first relapse.1 Below are some things to discuss with your patient before they start treatment to help prepare them for what to expect, and who to contact if they experience any side effects.
Before starting treatment with BLENREP, help your eligible patients understand what type of side effects they might experience and how these are detected
Patients should be made aware of whom to contact if they experience any side effects, as well as where and when to go for their eye examinations
Haematologists should collaborate with eye care professionals for support in monitoring and managing eye-related side effects1
Ophthalmic examinations should be performed by an eye care professional (ophthalmologist or optometrist) before the first 4 doses of BLENREP, and as clinically indicated thereafter.1
During the examination, eye care professionals will perform a slit lamp examination and visual acuity test.1
Slit lamp examination: An examination is performed with a slit lamp to identify any changes to the surface of the eye.
Visual acuity test: Patients are asked to read the letters on a chart that is a set distance from the eyes (Snellen eye chart).
Roles and responsibilities of haematologists and eye care professionals for BLENREP eye care
| Haematologists’ responsibilities | Eye care professionals’ responsibilities |
|---|---|
Referring your patients to an eye care professional and providing them with:
The haematologist is responsible for implementing any dose modifications of BLENREP to manage eye-related side effects:
The dose of BLENREP should NOT be re-escalated after a dose reduction due to eye-related side effects. |
Eye care professionals conduct:1
The eye care professional will indicate severity according to the corneal examination and BCVA findings grading table guidelines and send the completed form to the prescriber of BLENREP. If there is a decline in BCVA compared to baseline examinations, they will determine the relationship to BLENREP. They will indicate the highest severity grading of ophthalmic finding (out of both corneal examination, and BCVA findings) in the most severely affected eye. |
Since both eyes may not be affected to the same degree, the worst severity will be reported for the most severely affected eye.1
Practical eye care advice for patients on BLENREP
Administer preservative-free artificial tears at least 4 times a day
Avoid contact lenses until end of treatment*
Use caution when driving or operating machinery and avoid these activities if vision is affected
Contact their prescriber/ eye care doctor promptly if they experience eye-related side effects
*Bandage contact lenses may be used under the direction of an ophthalmologist.
Questions to ask your patients to assess side effects associated with BLENREP
Asking your patient about any new symptoms and reporting these supports detection and management, including dose modification, and helps patients to stay on treatment where appropriate.1
Here are some questions to consider asking your patients to ensure they have the support they need and aren’t experiencing any side effects that you are not aware of.
Questions that you could ask your patients:
General:
Eye-related side effects:
Abbreviations
BCVA, best corrected visual acuity; BPd, belantamab mafodotin, bortezomib and dexamethasone; BVd, belantamab mafodotin, bortezomib and dexamethasone; EMC, electronic medicine compendium; SPC, summary of product characteristics.
References
- BLENREP Summary of Product Characteristics. GlaxoSmithKline; 2025.
- EMC. Blenrep 100 mg powder for concentrate for solution for infusion - Risk Management Materials. Available from https://www.medicines.org.uk/emc/product/100782/rmms. Accessed October 2025.
▼This product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (available on the Apple App Store or Google Play Store). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.
October 2025 | PM-GB-BLM-WCNT-250006 (V1.0)
